Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

EssilorLuxottica: Q4/FY 2025 Results - Revenue growing 18.4% in Q4 and 11.2% in the FY. Adj. operating margin at 16.0% in the FY

globenewswire.com
EL The company reported record double-digit sales growth for the year and a strong Q4, despite macroeconomic headwinds and US tariffs. They are confident in continued momentum and are updating their five-year outlook positively.

Revenue 1 growing 18.4% in Q4 and 11.2% in the FY

Adj. operating margin 1 ,2 at 16.0% in the FY

Paris, France (February 11, 2026 - 6:00 pm) – The Board of Directors of EssilorLuxottica met on February 11, 2026 to approve the consolidated financial statements for the year ended December 31, 2025. These financial statements were audited by the Statutory Auditors whose audit report is in the process of being issued.

Francesco Milleri, Chairman and CEO, and Paul du Saillant, Deputy CEO at EssilorLuxottica commented: “This year marks a historic milestone: for the first time in EssilorLuxottica’s history, we delivered annual double-digit sales growth at constant currency, following another record quarter in Q4, up 18.4%. In an uncertain macroeconomic and geopolitical environment, and despite headwinds from US tariffs, we reached record earnings, while making bold investments to advance our innovation agenda.

This sharp acceleration reflects the depth of our leadership across all our activities and our new categories, capable of generating sustained value for our stakeholders and for the industry as a whole. Our success in wearables is helping to propel the AI-glasses revolution, with our iconic brands being a powerful driver of demand. At the same time, our breakthroughs in medtech, myopia management and audiology are cementing our role as a leader across multiple frontiers.

We have every region and every business to thank for these results. Our teams have shown remarkable resilience and ability to embrace our new disruptive agenda. We are confident that this momentum will continue, confirming the strength and relevance of our vision and the excellence of our execution. While we confirm to be on track with the five-year outlook communicated in March 2022, today we’re updating it. Looking ahead to the next five years, we are committed to delivering solid revenue growth, with the adjusted operating profit’s pace broadly aligned, as we lead our Company decisively into its medtech transformation journey.”

Attachment